Physician profile
Christopher A Edge
NPI 1447233184
$1,804.14
in general payments reported to CMS, 2019-2025
26 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $328 · 2021: $326 · 2022: $266 · 2023: $175 · 2024: $238 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $213.35 | 2020-2025 | Airsupra |
| Lilly USA, LLC | $201.05 | 2020-2025 | Jardiance, Trulicity, Mounjaro |
| Pfizer INC. | $172.99 | 2019-2025 | |
| Amgen INC. | $151.95 | 2021-2025 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $136.83 | 2021-2022 | |
| Antares Pharma, INC. | $103.51 | 2019-2021 | |
| Glaxosmithkline, LLC. | $87.57 | 2019-2023 | Trelegy Ellipta |
| Adlon Therapeutics L.P. | $79.67 | 2020-2021 | |
| Amarin Pharma, INC. | $65.54 | 2019-2020 | |
| Medtronic, INC. | $60.54 | 2022-2025 | Synchromedii, Intellis Adaptivestim |
| Forte Bio-Pharma LLC | $59.99 | 2025 | Prolate, Tanlor, Nalocet |
| Abbvie INC. | $53.61 | 2021-2023 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.38 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $44.31 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $44.10 | 2024 | Recorlev |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $39.39 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $38.60 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $32.48 | 2021-2022 | |
| Nevro Corp. | $29.98 | 2023 | Senza |
| Eisai INC. | $26.05 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $22.98 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.01 | 2022 | |
| Boston Scientific Corporation | $19.32 | 2025 | Watchman Flx |
| Viatris Specialty LLC | $16.87 | 2025 | Yupelri |
| Exact Sciences Corporation | $16.50 | 2024 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Edge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.